{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:49:13Z","timestamp":1790790553363,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-025-02008-w","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T07:46:59Z","timestamp":1753343219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of polycystic ovary syndrome on the atherogenic plasma index: A retrospective analysis"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0737-2360","authenticated-orcid":false,"given":"Huseyin","family":"Demirci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1010-110X","authenticated-orcid":false,"given":"Burak","family":"Menekse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6858-751X","authenticated-orcid":false,"given":"Enes","family":"Ucgul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3063-3409","authenticated-orcid":false,"given":"Yuksel","family":"Onaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1459-5765","authenticated-orcid":false,"given":"Seyit Murat","family":"Bayram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4455-7276","authenticated-orcid":false,"given":"Erman","family":"Cakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"issue":"3","key":"2008_CR1","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00404-024-07607-x","volume":"310","author":"N Salari","year":"2024","unstructured":"Salari N, Nankali A, Ghanbari A, Jafarpour S, Ghasemi H, Dokaneheifard S, et al. Global prevalence of polycystic ovary syndrome in women worldwide: a comprehensive systematic review and meta-analysis. Arch Gynecol Obstet. 2024;310(3):1303\u201314.","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"2008_CR2","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.3390\/jcm12041454","volume":"12","author":"S Singh","year":"2023","unstructured":"Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, et al. Polycystic ovary syndrome: etiology, current management, and future therapeutics. J Clin Med. 2023;12(4):1454.","journal-title":"J Clin Med"},{"issue":"1","key":"2008_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/ejendo\/lvad077","volume":"189","author":"M-M Ollila","year":"2023","unstructured":"Ollila M-M, Arffman RK, Korhonen E, Morin-Papunen L, Franks S, Junttila J, et al. Women with PCOS have an increased risk for cardiovascular disease regardless of diagnostic criteria\u2014a prospective population-based cohort study. Eur J Endocrinol. 2023;189(1):96\u2013105.","journal-title":"Eur J Endocrinol"},{"key":"2008_CR4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cca.2019.11.003","volume":"502","author":"X Zeng","year":"2020","unstructured":"Zeng X, Xie Y-j, Liu Y-t, Long S-l. Mo Z-c. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214\u201321.","journal-title":"Clin Chim Acta"},{"issue":"7","key":"2008_CR5","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.3390\/biomedicines10071700","volume":"10","author":"J Nawrocka-Rutkowska","year":"2022","unstructured":"Nawrocka-Rutkowska J, Szyd\u0142owska I, Jakubowska K, Olszewska M, Chlubek D, Szczuko M, et al. The role of oxidative stress in the risk of cardiovascular disease and identification of risk factors using AIP and Castelli atherogenicity indicators in patients with PCOS. Biomedicines. 2022;10(7):1700.","journal-title":"Biomedicines"},{"issue":"2","key":"2008_CR6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3390\/metabo13020302","volume":"13","author":"M Jabczyk","year":"2023","unstructured":"Jabczyk M, Nowak J, Jagielski P, Hudzik B, Kulik-Kupka K, W\u0142odarczyk A, et al. Metabolic deregulations in patients with polycystic ovary syndrome. Metabolites. 2023;13(2):302.","journal-title":"Metabolites"},{"issue":"12","key":"2008_CR7","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3390\/metabo11120869","volume":"11","author":"W Chen","year":"2021","unstructured":"Chen W, Pang YJM. Metabolic syndrome and PCOS: pathogenesis and the role of metabolites. Metabolites. 2021;11(12):869.","journal-title":"Metabolites"},{"issue":"2","key":"2008_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/0003319720949804","volume":"72","author":"L Wang","year":"2021","unstructured":"Wang L, Chen F, Xiaoqi C, Yujun C, Zijie L. Atherogenic index of plasma is an independent risk factor for coronary artery disease and a higher SYNTAX score. Angiology. 2021;72(2):181\u20136.","journal-title":"Angiology"},{"issue":"3","key":"2008_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.amjms.2021.05.001","volume":"362","author":"Y Si","year":"2021","unstructured":"Si Y, Fan W, Han C, Liu J, Sun L. Atherogenic index of plasma, triglyceride-glucose index and monocyte-to-lymphocyte ratio for predicting subclinical coronary artery disease. Am J Med Sci. 2021;362(3):285\u201390.","journal-title":"Am J Med Sci"},{"key":"2008_CR10","doi-asserted-by":"crossref","unstructured":"Raaj I, Thalamati M, Gowda V, Rao A. The role of the atherogenic index of plasma and the Castelli risk index I and II in cardiovascular disease. Cureus. 2024;16(11).","DOI":"10.7759\/cureus.74644"},{"issue":"3","key":"2008_CR11","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1210\/jc.2005-2501","volume":"91","author":"S Franks","year":"2006","unstructured":"Franks S. Diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab. 2006;91(3):786\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2008_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/ijt.ijt_93_16","volume":"9","author":"R Aswini","year":"2017","unstructured":"Aswini R, Jayapalan S. Modified Ferriman\u2013Gallwey score in hirsutism and its association with metabolic syndrome. Int J Trichology. 2017;9(1):7\u201313.","journal-title":"Int J Trichology"},{"issue":"4","key":"2008_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/cen.14421","volume":"95","author":"TM Barber","year":"2021","unstructured":"Barber TM, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol. 2021;95(4):531\u201341.","journal-title":"Clin Endocrinol"},{"issue":"3","key":"2008_CR14","doi-asserted-by":"publisher","first-page":"564","DOI":"10.5455\/annalsmedres.2021.01.010","volume":"28","author":"E Bozkurt","year":"2021","unstructured":"Bozkurt E, Beysel S, Vurmaz A, Atay E, Gokaslan S, Ertekin A. Evaluation of relationship among polycystic ovary syndrome, atherogenic index of plasma, and high sensitive C reactive protein. Ann Med Res. 2021;28(3):564\u201370.","journal-title":"Ann Med Res"},{"issue":"4","key":"2008_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.tjog.2019.05.003","volume":"58","author":"Q Liu","year":"2019","unstructured":"Liu Q, Xie Y-j, Qu L-h, Zhang M-x. Mo Z-c. Dyslipidemia involvement in the development of polycystic ovary syndrome. Taiwan J Obstet Gynecol. 2019;58(4):447\u201353.","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"4","key":"2008_CR16","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1515\/jomb-2017-0068","volume":"37","author":"E Bakeer","year":"2018","unstructured":"Bakeer E, Radwan R, El Mandoury A, Abd El Rahman A, Gad M, Abd El Maksoud S. Anti-m\u00fcllerian hormone as a diagnostic marker in Egyptian infertile polycystic ovary syndrome females: correlations with vitamin D, total testosterone, dyslipidemia and anthropometric parameters. J Med Biochem. 2018;37(4):448.","journal-title":"J Med Biochem"},{"issue":"7","key":"2008_CR17","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.fertnstert.2018.08.046","volume":"110","author":"S Behboudi-Gandevani","year":"2018","unstructured":"Behboudi-Gandevani S, Tehrani FR, Hosseinpanah F, Khalili D, Cheraghi L, Kazemijaliseh H, et al. Cardiometabolic risks in polycystic ovary syndrome: long-term population-based follow-up study. Fertil Steril. 2018;110(7):1377\u201386.","journal-title":"Fertil Steril"},{"issue":"5","key":"2008_CR18","first-page":"526","volume":"4","author":"\u015e G\u00f6k\u00e7e","year":"2021","unstructured":"G\u00f6k\u00e7e \u015e, Herkilo\u011flu D. Cardiovascular risk factors in polycystic ovary syndrome; the relationship of dyslipidemia and obesity. J Health Sci Med. 2021;4(5):526\u201331.","journal-title":"J Health Sci Med"},{"key":"2008_CR19","doi-asserted-by":"crossref","unstructured":"Yang J, Chen C. Hormonal changes in PCOS. J Endocrinol. 2024;261(1).","DOI":"10.1530\/JOE-23-0342"},{"issue":"12","key":"2008_CR20","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.3390\/diagnostics12122924","volume":"12","author":"M Saei Ghare Naz","year":"2022","unstructured":"Saei Ghare Naz M, Mousavi M, Mahboobifard F, Niknam A, Ramezani Tehrani F. A meta-analysis of observational studies on prolactin levels in women with polycystic ovary syndrome. Diagnostics. 2022;12(12):2924.","journal-title":"Diagnostics"},{"key":"2008_CR21","doi-asserted-by":"crossref","unstructured":"Delcour C, Robin G, Young J, Dewailly D. PCOS and hyperprolactinemia: what do we know in 2019? Ther Adv Reprod Health. 2019;13.","DOI":"10.1177\/1179558119871921"},{"issue":"5","key":"2008_CR22","doi-asserted-by":"publisher","first-page":"517","DOI":"10.18621\/eurj.668471","volume":"6","author":"G Adanas","year":"2020","unstructured":"Adanas G, \u00d6zsoy HGT. The relationship between prolactin and adipose tissue and metabolic parameters in patients with polycystic ovary syndrome. Eur Res J. 2020;6(5):517\u201326.","journal-title":"Eur Res J"},{"issue":"8","key":"2008_CR23","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/humrep\/deu133","volume":"29","author":"D Glintborg","year":"2014","unstructured":"Glintborg D, Altinok M, Mumm H, Buch K, Ravn P, Andersen M. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome. Hum Reprod. 2014;29(8):1773\u20139.","journal-title":"Hum Reprod"},{"key":"2008_CR24","doi-asserted-by":"publisher","first-page":"1015520","DOI":"10.3389\/fendo.2022.1015520","volume":"13","author":"R Pirchio","year":"2022","unstructured":"Pirchio R, Graziadio C, Colao A, Pivonello R, Auriemma RS. Metabolic effects of prolactin. Front Endocrinol. 2022;13:1015520.","journal-title":"Front Endocrinol"},{"issue":"5","key":"2008_CR25","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.fertnstert.2022.03.009","volume":"117","author":"C Guan","year":"2022","unstructured":"Guan C, Zahid S, Minhas AS, Ouyang P, Vaught A, Baker VL, et al. Polycystic ovary syndrome: a risk-enhancing factor for cardiovascular disease. Fertil Steril. 2022;117(5):924\u201335.","journal-title":"Fertil Steril"},{"issue":"7","key":"2008_CR26","doi-asserted-by":"publisher","first-page":"966","DOI":"10.3390\/healthcare11070966","volume":"11","author":"B Lioy","year":"2023","unstructured":"Lioy B, Webb RJ, Amirabdollahian F. The association between the atherogenic index of plasma and cardiometabolic risk factors: a review. Healthcare. 2023;11(7):966.","journal-title":"Healthcare"},{"issue":"1","key":"2008_CR27","doi-asserted-by":"publisher","first-page":"31092","DOI":"10.1038\/s41598-024-82305-x","volume":"14","author":"Q Zeng","year":"2024","unstructured":"Zeng Q, Zhong Q, Zhao L, An Z, Li S. Combined effect of triglyceride-glucose index and atherogenic index of plasma on cardiovascular disease: a National cohort study. Sci Rep. 2024;14(1):31092.","journal-title":"Sci Rep"},{"key":"2008_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12872-021-02432-5","volume":"21","author":"A Afsin","year":"2021","unstructured":"Afsin A, Kaya H, Suner A, Uzel KE, Bursa N, Hosoglu Y, et al. Plasma atherogenic indices are independent predictors of slow coronary flow. BMC Cardiovasc Disord. 2021;21:1\u20139.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"2008_CR29","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12902-024-01701-6","volume":"24","author":"E Uysal","year":"2024","unstructured":"Uysal E, Tammo O, Soylemez E, Inceb\u0131y\u0131k M, Filiz D, Alci M. Significance of measuring anthropometric and atherogenic indices in patients with polycystic ovary syndrome. BMC Endocr Disord. 2024;24(1):160.","journal-title":"BMC Endocr Disord"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-02008-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-025-02008-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-02008-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T21:23:31Z","timestamp":1757280211000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-025-02008-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2008"],"URL":"https:\/\/doi.org\/10.1186\/s12902-025-02008-w","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Ankara Etlik City Hospital Ethics Committee (Ethics Committee Number: AE\u015eH-BADEK-2025-0001). The study was conducted in accordance with the principles of the Declaration of Helsinki. Due to the retrospective nature of our research, informed consent from participation was not deemed necessary by the Ankara Etlik City Hospital Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}